All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-11-16T22:06:43.000Z

Allo-SCT outcomes in R/R T-cell lymphoma

Nov 16, 2018
Share:

Bookmark this article

On 9 November 2018, Gerald Wulf from University Medicine Göttingen, Göttingen, DE, and colleagues, published in Bone Marrow Transplantation an outcome analysis of allogeneic stem cell transplantation in relapsed or refractory (R/R) T-cell lymphoma patients.

Salvage chemotherapy is the standard of care for patients with peripheral T-cell lymphoma but leads to disease remission in approximately 30% of patients. Allogeneic stem cell transplantation (allo-SCT) or bone marrow transplantation (BMT) has been considered as a treatment option for R/R T-cell lymphoma patients but its efficacy and safety are still under consideration. The aim of this study was to analyze the outcomes of allo-SCT or -BMT in R/R T-cell lymphoma patients, following conditioning with fludarabine, busulfan, and cyclophosphamide (FBC). Outcome endpoints included overall survival (OS), disease-free survival, non-relapse mortality (NRM), and graft-versus-host disease (GvHD).

Study design

  • Study duration: August 2003–April 2013
  • N = 84 patients with histological T-cell lymphoma subtype, who were eligible for allo-SCT or BMT
  • All patients received lymphoma-myeloablative conditioning (FBC) containing:
    • Fludarabine: intravenously (IV), 25 mg/m2 per day from Day -8 to Day -4 prior to transplantation
    • Busulfan: orally, 4 mg/kg per day or IV, 3.2 mg/kg per day from Day -6 to Day -4
    • Cyclophosphamide: IV, 60 mg/kg per day on Day -3 and Day -2
  • For GvHD prophylaxis, tacrolimus (8–12 µg/L) and mycophenolate mofetil (1 g twice a day until Day 28) were administered on Day -1
  • Antithymocyte globulin (ATG) was administered in n = 32 patients, who underwent unrelated or mismatched transplants

Results

  • At a median follow-up of 14.5 months (range, 1.5–114):
    • OS: 38.2% (95% CI, 33–44)
    • Disease-free survival: 37.2% (95% CI, 32–43)
    • No disease-related deaths occurred after month 11
  • Risk factor analysis revealed that OS was significantly impacted by the following factors:
    • Pre-transplantation International Prognostic Index (IPI) > 3 (poor survival subgroup; P = 0.001210)
    • Elevated serum lactate dehydrogenase (LDH)
    • High Eastern Cooperative Oncology Group (ECOG) status
    • Patients with progressive disease (PD) had dismal outcome compared to patients achieving complete response (CR), partial response (PR) or stable disease (SD) in response to salvage chemotherapy (P = 0.0866)
  • Donor type or ATG use did not separate patients into different outcome subgroups
  • At 100 days post-transplantation (n = 71), the patient status was as follows:
    • CR: 45 patients
    • PR: 7 patients
    • SD: 2 patients
    • PD: 17 patients
  • Patients experiencing acute GvHD (aGvHD) had a significantly higher OS (improvement for patients with overall aGvHD Grade 1–4; P = 0.0035). This effect was not seen in patients with chronic GvHD (cGvHD; P = 0.7241)
  • NRM occurred in 35 patients:
    • One-year NRM: 13.1%
    • Three-year NRM: 32.3%
    • Five-year NRM: 46%
  • The one-year estimate for GvHD- and relapse-free survival was 50.9% (95% CI, 45.4–56.4)

The results of this retrospective analysis revealed that allo-SCT or -BMT provided disease remission in approximately 38% of R/R T-cell lymphoma patients at a three-year follow-up. Moreover, OS was significantly lowered by prior high-dose chemotherapy with autologous SCT, increasing IPI, elevated LDH, ECOG > 1 and remission status before transplantation. According to the authors, allo-SCT is a curative treatment for a number of T-cell lymphoma patients and FBC an efficient conditioning regimen for advanced disease stages.

  1. Wulf G. et al. Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease. Bone Marrow Transplant. 2018 Nov 9. DOI: 10.1038/s41409-018-0360-9. [Epub ahead of print]

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox